Legislation to Enact Prescription Drug Price Controls

SB 483, SB 484 and SB 485 were introduced in mid-September 2023 that would establish a new state board – a so-called Prescription Drug Affordability Board (PDAB) – that would determine how much pharmaceutical companies can charge for certain drugs by setting an “upper price limit”. According to PDAB supporters, such a body would lower…

Read More

So Close on Reestablishing State R&D Tax Credit…

Early fall 2023 saw a package of bills introduced that would reestablish a state research & development R&D) tax credit in Michigan – HBs 5099, 5100, 5101 and 5102. Ever since Michigan moved from the Michigan Business Tax regime to the current Corporate Income Tax regime twelve years ago, Michigan taxpayers have not been afforded…

Read More

Repeal of R&D Amortization

The America Innovation and R&D Competitiveness Act of 2023 or HB 2673 was reintroduced that would repeal current rules and allow a business to deduct of R&D costs in the tax year that they occur and thereby incentivize long-term investments in innovation. Such repeal has been a top policy priority for MichBio and the bio-industry generally…

Read More

White House Announces New Efforts to Target Prescription Drug Prices

On December 7, the Biden Administration announced new efforts intended to lower prescription drug costs. While the announcement includes broader initiatives, one component would allow invoking March-In rights under the Bayh-Dole Act to license the patent rights of drugs to other biopharmaceutical manufacturers when the price of the drug is deemed to be too high. MichBio has grave…

Read More

FTC, DOJ Finalize Merger Guidelines that Could Impede Healthcare Deals

The Federal Trade Commission (FTC) and Department of Justice (DOJ) released new merger guidelines that have implications for the life sciences industry. The new guidelines may give regulators more ammunition to go after vertical and cross-market M&A that has historically been more difficult to challenge. Private equity “roll-ups” of multiple companies may also face heightened scrutiny. The…

Read More

Michigan Health Information Network Announces Appointment of Janée Tyus to its Board of Directors

Original Source Tyus brings over a decade of experience in advancing health equity, improving access to the Board EAST LANSING, Mich. – The Michigan Health Information Network Shared Services (MiHIN), Michigan’s state designated health information exchange, today announced that Janée Tyus, MPH has been elected to its Board of Directors. Tyus will bring over a decade of…

Read More

TrialAssure Uses Artificial Intelligence to Create Plain Language Summaries for 50,000 Studies Listed on ClinicalTrials.Gov

ORIGINAL SOURCE TrialAssure’s proprietary AI-technology can aid in making clinical trial results available more quickly to all trial participants and the public The equivalent of one million work hours completed in less than one day using AI in honor of Health Literacy Month Plain language summaries to be released over a five-week period by disease…

Read More

TrialAssure Announces AI Generative Text Partnership with Top Clinical Research Organization MMS on New Medical Writing Initiative

TrialAssure, a leading software-as-a-service (SaaS) provider advancing clinical trial disclosure, data sharing, and transparency, announced today that it is collaborating with MMS, a global clinical research organization, on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development. The primary focus of this collaboration…

Read More

New Day Foundation for Families Announces New Day NEXT

ROCHESTER HILLS, MICH, July 1, 2023 — New Day Foundation for Families is proud to announce the launch of New Day NEXT, a young professionals’ group of passionate and motivated friends designed to cultivate the next generation of philanthropy, along with the group’s first event – a brunch following New Day’s 5K Run on Sat.,…

Read More